huHSC-NCG-hIL2 Mouse Model For Non-clinical ADCC Efficacy Evaluation
In recent years, antibody-dependent cell-mediated cytotoxicity (ADCC) has played a crucial role in the development of antibody drugs. And the human IgG Fc receptor FcγRIIIA (CD16A) is mainly responsible for triggering NK cell-mediated ADCC, but its homologous gene FcγRIV is not expressed in mouse NK cells. Therefore, it is difficult to accurately evaluate the ADCC activity of human therapeutic antibody drugs using traditional mouse NK models.
To solve this problem, Gempharmatech has developed huHSC-NCG-hIL2 immune system humanized mouse model that can efficiently reconstruct human NK cells, providing a new solution for evaluating the ADCC activity of antibody drugs.
Figure 1. Reconstitution levels of peripheral blood lymphocytes in huHSC-NCG-hIL2 mice
Application of huHSC-NCG-hIL2 mice in non-clinical efficacy evaluation of ADCC antibodies.
(Drug 1:ADCC enhanced drug)
Figure 2. Evaluation of ADCC effect of human NK cells from huHSC-NCG-hIL2 mice spleen in vitro
HSC-NCG-IL2+JIMT1
Figure 3. Efficacy evaluation of ADCC drugs in huHSC-NCG-hIL2 bearing JIMT-1 tumor model
The results show that huHSC-NCG-hIL2 mice can be used for non-clinical in vitro and in vivo efficacy evaluation of ADCC antibodies, and can reflect the differences in efficacy between ADCC-enhanced antibodies and ADCC conventional antibody drugs.
In summary, the huHSC-NCG-hIL2 mouse model developed by Gempharmatech can quickly and efficiently reconstruct human NK cells, which can be used for the non-clinical efficacy evaluation of ADCC antibodies and provide information for the development and clinical application of antibody drugs. Gempharmatech has 160+ CDX cell lines, which can be used with huHSC-NCG-hIL2 mice to construct dual humanized tumor-immune models to meet the non-clinical research and development needs of drugs with different targets and indications.
Visit our website to learn more: https://en.gempharmatech.com/index.html